iNtRON Biotechnology Inc (048530) — Financial Flexibility Index
iNtRON Biotechnology Inc (048530) has a Financial Flexibility Index of -0.21x as of September 2025. Free cash flow of ₩-993.53 Million (operating CF ₩-993.53 Million minus capex ₩0.00) represents 0% of total liabilities (₩4.73 Billion). Check iNtRON Biotechnology Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
iNtRON Biotechnology Inc Financial Flexibility Index (2012–2024)
Historical Financial Flexibility Index trend for iNtRON Biotechnology Inc across 11 annual periods. See 048530 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for iNtRON Biotechnology Inc (2012–2024)
Year-by-year free cash flow to debt coverage for iNtRON Biotechnology Inc. For the full company profile including market capitalisation, see iNtRON Biotechnology Inc market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.40x | ₩1.05 Billion | ₩-138.47 Million | ₩2.60 Billion | ▼ -94.0% |
| 2023 | 6.74x | ₩12.67 Billion | ₩3.12 Billion | ₩1.88 Billion | ▲ +2755.7% |
| 2022 | 0.24x | ₩8.21 Billion | ₩5.98 Billion | ₩34.78 Billion | ▼ -37.1% |
| 2021 | 0.38x | ₩19.52 Billion | ₩16.47 Billion | ₩52.02 Billion | ▼ -52.5% |
| 2020 | 0.79x | ₩11.98 Billion | ₩7.13 Billion | ₩15.16 Billion | ▲ +3815.8% |
| 2019 | -0.02x | ₩-512.11 Million | ₩-812.48 Million | ₩24.07 Billion | ▼ -107.0% |
| 2018 | 0.30x | ₩4.75 Billion | ₩4.20 Billion | ₩15.70 Billion | ▲ +203.6% |
| 2017 | -0.29x | ₩-4.49 Billion | ₩-5.47 Billion | ₩15.38 Billion | ▼ -3918.3% |
| 2016 | 0.01x | ₩79.99 Million | ₩-4.64 Billion | ₩10.46 Billion | ▼ -99.4% |
| 2015 | 1.35x | ₩8.00 Billion | ₩1.70 Billion | ₩5.93 Billion | ▲ +6382.5% |
| 2012 | 0.02x | ₩160.60 Million | ₩-331.01 Million | ₩7.72 Billion | — |